U.S. Markets closed
  • S&P Futures

    4,166.25
    -10.00 (-0.24%)
     
  • Dow Futures

    33,990.00
    -91.00 (-0.27%)
     
  • Nasdaq Futures

    14,005.25
    -24.25 (-0.17%)
     
  • Russell 2000 Futures

    2,259.00
    +3.30 (+0.15%)
     
  • Crude Oil

    62.77
    -0.36 (-0.57%)
     
  • Gold

    1,783.10
    +2.90 (+0.16%)
     
  • Silver

    26.14
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1959
    -0.0021 (-0.1794%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3815
    -0.0024 (-0.1755%)
     
  • USD/JPY

    108.7500
    -0.0330 (-0.0303%)
     
  • BTC-USD

    56,895.83
    -4,072.01 (-6.68%)
     
  • CMC Crypto 200

    1,288.13
    -103.58 (-7.44%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,650.64
    -32.73 (-0.11%)
     

Antibe Therapeutics Announces C$35 Million Bought Deal Public Offering

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

/NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

TORONTO, Feb. 17, 2021 /CNW/ - Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX: ATE) today announced that it has entered into an agreement with Canaccord Genuity Corp. on behalf of a syndicate of underwriters (together, the "Underwriters") and pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 5,850,000 units (the "Offered Securities") in the capital of the Company at a price of C$6.00 per Offered Security (the "Offering Price") for aggregate gross proceeds to the Company of C$35,100,000 (the "Offering").

Each Offered Security shall consist of one common share (a "Common Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant shall entitle the holder thereof to acquire one Common Share at an exercise price per Common Share of C$7.50 for a period of 36 months from the closing of the Offering.

The Company intends to use the net proceeds of the Offering to fully fund the adaptive Phase III efficacy trial and remaining non-clinical studies for its lead drug, complete IND-enabling studies for its second and third pipeline drugs, advance new anti-inflammatory drug candidates and for working capital and general corporate purposes, all as more fully described in the prospectus.

The Offered Securities will be offered in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, pursuant to a prospectus supplement to be dated on or about February 19, 2021 to the Company's base shelf prospectus dated January 12, 2021 (the "Prospectus") and elsewhere in compliance with applicable securities laws.

The closing of the Offering is expected to occur on or about February 24, 2021 and is subject to the completion of formal documentation and receipt of all regulatory approvals, including the approval of the Toronto Stock Exchange.

In addition, the Company intends to grant the Underwriters a 30-day option to purchase up to an additional 15% of the Offered Securities pursuant to the proposed Offering on the same terms and conditions.

Copies of the Prospectus, following filing thereof, may be obtained on SEDAR at www.sedar.com and from Canaccord Genuity Corp., 161 Bay Street, Suite 3000, Toronto, ON M5J 2S1. The Prospectus contains important detailed information about the Company and the proposed Offering. Prospective investors should read the Prospectus and the other documents the Company has filed on SEDAR at www.sedar.com before making an investment decision.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or "U.S. persons" (as such term is defined in Regulation S promulgated under the U.S. Securities Act) absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Antibe Therapeutics Inc.
Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. Antibe's current pipeline includes three assets that seek to overcome the gastrointestinal ("GI") ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe's lead drug, otenaproxesul (formerly ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. The Company's next target is inflammatory bowel disease ("IBD"), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the possible exercise of the Over-Allotment Option, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company's inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Antibe Therapeutics Inc

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/February2021/17/c8332.html